Fabrice André
Impact in
- Cancer Research top 0.01%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 0.02%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
Papers in
- Cancer Research 278
- Breast Cancer Treatment Studies 185
- Cancer Genomics and Diagnostics 102
- Oncology 182
- HER2/EGFR in Cancer Research 56
- Cancer Immunotherapy and Biomarkers 49
- Cancer survivorship and care 27
- Co-authors
- Jean‐Charles Soria (70 shared papers)Laurence Zitvogel (33 shared papers)Lajos Pusztai (40 shared papers)Massimo Cristofanilli (22 shared papers)Nicholas C. Turner (25 shared papers)Sibylle Loibl (27 shared papers)Suzette Delaloge (76 shared papers)Gabriel N. Hortobágyi (31 shared papers)
- Journals
- Annals of Oncology (160 papers)Journal of Clinical Oncology (47 papers)Clinical Cancer Research (31 papers)ESMO Open (27 papers)European Journal of Cancer (27 papers)
- Partner nations
- FranceUnited StatesItaly
In The Last Decade
Fabrice André
625 papers receiving 81.4k citations
Fabrice André's Hit Papers
Peers
Comparison fields: 5 of 179
- Cancer Research 26k
- Oncology 20.6k
- Pulmonary and Respiratory Medicine 17.3k
- Immunology 5.9k
- Molecular Biology 13.3k
Countries citing papers authored by Fabrice André
This map shows the geographic impact of Fabrice André's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fabrice André with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fabrice André more than expected).
Fields of papers citing papers by Fabrice André
This network shows the impact of papers produced by Fabrice André. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fabrice André. The network helps show where Fabrice André may publish in the future.
Co-authors
The 25 scholars most cited alongside Fabrice André, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 648 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Hit paper breakdown → | 2013 | 2987 |
| 2 | Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy Hit paper breakdown → | 2007 | 2660 |
| 3 | Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer Hit paper breakdown → | 2008 | 2394 |
| 4 | Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer Hit paper breakdown → | 2019 | 2016 |
| 5 | 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) Hit paper breakdown → | 2016 | 1808 |
| 6 | Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors Hit paper breakdown → | 2009 | 1668 |
| 7 | Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer Hit paper breakdown → | 2019 | 1606 |
| 8 | Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer Hit paper breakdown → | 2016 | 1564 |
| 9 | AACR Project GENIE: Powering Precision Medicine through an International Consortium Hit paper breakdown → | 2017 | 1472 |
| 10 | Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 Hit paper breakdown → | 2015 | 1470 |
| 11 | DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy Hit paper breakdown → | 2006 | 1427 |
| 12 | Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer Hit paper breakdown → | 2015 | 1313 |
| 13 | Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial Hit paper breakdown → | 2005 | 1127 |
| 14 | 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) Hit paper breakdown → | 2020 | 1029 |
| 15 | ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer Hit paper breakdown → | 2021 | 1015 |
| 16 | Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer Hit paper breakdown → | 2018 | 958 |
| 17 | De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 Hit paper breakdown → | 2017 | 918 |
| 18 | Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy Hit paper breakdown → | 2014 | 903 |
| 19 | Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group Hit paper breakdown → | 2020 | 890 |
| 20 | 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) Hit paper breakdown → | 2018 | 884 |
About Fabrice André
Fabrice André is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Molecular Biology and Immunology, having authored 648 papers that have together received 83.1k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (185 papers), Cancer Genomics and Diagnostics (102 papers), Advanced Breast Cancer Therapies (85 papers), HER2/EGFR in Cancer Research (56 papers), Cancer Immunotherapy and Biomarkers (49 papers), Lung Cancer Treatments and Mutations (43 papers), Cancer survivorship and care (27 papers) and Immunotherapy and Immune Responses (26 papers). The work is most often cited by research in Cancer Research (26k citations), Oncology (20.6k citations), Pulmonary and Respiratory Medicine (17.3k citations), Immunology (5.9k citations) and Molecular Biology (13.3k citations). Fabrice André has collaborated with scholars based in France, United States and Italy. Frequent co-authors include Jean‐Charles Soria, Laurence Zitvogel, Lajos Pusztai, Massimo Cristofanilli, Nicholas C. Turner, Sibylle Loibl, Suzette Delaloge, Gabriel N. Hortobágyi, Sherene Loi and W. Fraser Symmans. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Clinical Cancer Research, ESMO Open and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.